CLINICAL EFFECTIVENESS OF THE MODIFIED RELEASE TRIMETAZIDINE IN MICROVASCULAR ANGINA
https://doi.org/10.15829/1560-4071-2016-12-84-89
Abstract
Aim. Assessment of clinical effectiveness of trimetazidine MR (Preductal MR® , Les Laboratoires Servier) in patients with microvascular angina.
Material and methods. Totally, 50 patients studied (mean age 55,16±3,82 y. o.) with microvascular angina primary (n=36) and secondary, related to arterial hypertension (n=14) and with remaining angina presentation of II-III FC at background of antianginal treatment of hemodynamic action. All patients, in addition to the performed treatment, were assigned with trimetazidine MR (TMR) with monthly control of antianginal efficacy during 6 months follow-up.
Results. The treatment led to significant decline of angina attacks from 21,24±12,57 to 5,44±3,11 (p<0,01) and dosages of short-acting nitrates from 18,08±13,87 to 2,86±2,66 (p<0,01) per month. So, the significant decrease in antianginal attacks was marked after one month of therapy and showed the raising effect by the 6th month of treatment. The effectivenes of TMR did not depend upon the condition of coronary arteries, gender, microvascular angina in more rapid reach of clinical effect in patients with the right type of myocardium circulation.
Conclusion. Introduction of Preductal MR® to the complex treatment of patients with microvascular angina does effectively control angina symptoms.
About the Authors
P. Yu. Galin
Orenburg State Medical University
Russian Federation
Russian Federation
T. G. Gubanova
Orenburg State Medical University
Russian Federation
Russian Federation
References
1. ESC guidelines on the management of stable coronary artery disease. European Heart Journal 2013; 34: 2949-3003.
2. Katzung, B. Basic & clinical pharmacology. 10th Ed.: McGraw-Hill Medical; 2007.
3. Aronov DM, Arutiunov GP, Belenkov YuN, et al. Тhe consensus of the experts about the appropriateness of myocardial cytoprotector Trimetazidine (Preduktal MV) in complex therapy of patients with chronic forms of ischemic heart disease. Cardiosomatic 2012; 3(2): 58-60. Russian (Аронов Д. М., Арутюнов Г. П., Беленков Ю. Н. и др. Согласованное мнение экспертов о целесообразности использования миокардиального цитопротектора триметазидина (Предуктала МВ) в комплексной терапии больных с хроническими формами ишемической болезни сердца. Кардиосоматика 2012, 3(2): 58-60).
4. Fihn SD, Gardin JM, Abrams J, et al. 2012 ACCF/AHA/ACP/ AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease. Circulation 2012; 126(25): 354-471.
5. Aronov DM. Expert consensus on the role and place of a myocardial cytoprotector, trimetazidine (Preductal MB), in treatment of patients with chronic forms of ischemic heart disease. Russ J Cardiol 2015; 14 (4): 256-26. Russian (Аронов Д. М. Экспертный консенсус о роли и месте миокардиального цитопротектора триметазидина (Предуктал МБ) в лечении больных с хроническими формами ишемической болезни сердца. Российский кардиологический журнал 2015; 14 (4): 256-26).
6. Bubnova MG, Aronov DM, Oganov RG, et al. New potential of Trimetazidine MB for coronary heart disease treatment in the real-world clinical practice: results of the Russian multi-centre randomised study PERSPECTIVE (Part II). Cardiovascular Therapy and Prevention 2011; 10(6): 70-80. Russian (Бубнова М. Г., Аронов Д. М., Оганов Р.Г. и др. Новые возможности триметазидина МВ в лечении ишемической болезни сердца в условиях реальной клинической практики. Результаты Российского многоцентрового рандомизированного исследования ПЕРСПЕКТИВА (часть II). Кардиоваскулярная терапия и профилактика 2011; 10(6): 70-80.
7. Oganov RG, Glezer MG, Deev AD. Program for detection of patients with ineffective therapy with beta-adrenoblockers and comparative assessment of efficacy of addition of trimetazidine MB or isosorbide dinitrate in stable angina. Results of a Russian study PARALLEL. Kardiologiia 2007; 3: 4-13. Russian (Оганов Р. Г., Глезер М. Г., Деев А. Д. Результаты Российского исследования ПАРАЛЛЕЛЬ: Программа по выявлению пациентов с неэффективной терапией β-адреноблокаторами и сравнительной оценке эффективности добавления к терапии триметазидина МВ или изосорбида динитрата при стабильной стенокардии. Кардиология 2007; 3: 4-13).
8. Vitale C, Spoletini I, Malorni W, et al. Efficacy of trimetazidine on functional capacity in symptomatic patients with stable exertional angina – the VASCO-angina study. International Journal of Cardiology 2013; 168(2): 1078-81.
9. Peng S, Zhao M, Wan J, et al. The efficacy of trimetazidine on stable angina pectoris: a meta-analysis of randomized clinical trials. International Journal of Cardiology 2014; 177 (3): 780-5.
10. Nesukay E. Assessment of the most effective combination of antianginal medications in the treatment of patients with stable angina pectoris. Circulation 2012 ; 15(125): 773.
Review
For citations:
Galin P.Yu., Gubanova T.G. CLINICAL EFFECTIVENESS OF THE MODIFIED RELEASE TRIMETAZIDINE IN MICROVASCULAR ANGINA. Russian Journal of Cardiology. 2016;(12):84-89. (In Russ.) https://doi.org/10.15829/1560-4071-2016-12-84-89
Views:
1284
Email this article 